| Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection RM Lynch, E Boritz, EE Coates, A DeZure, P Madden, P Costner, ... Science translational medicine 7 (319), 319ra206-319ra206, 2015 | 455 | 2015 |
| Chimpanzee adenovirus vector Ebola vaccine JE Ledgerwood, AD DeZure, DA Stanley, EE Coates, L Novik, ME Enama, ... New England Journal of Medicine 376 (10), 928-938, 2017 | 353 | 2017 |
| Extracellular matrix formation and mineralization on a phosphate-free porous bioactive glass scaffold using primary human osteoblast (HOB) cells JR Jones, O Tsigkou, EE Coates, MM Stevens, JM Polak, LL Hench Biomaterials 28 (9), 1653-1663, 2007 | 326 | 2007 |
| Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults Clinical & Experimental Immunology 182 (3), 289-301, 2015 | 268 | 2015 |
| Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults MR Gaudinski, EE Coates, KV Houser, GL Chen, G Yamshchikov, ... PLoS medicine 15 (1), e1002493, 2018 | 204 | 2018 |
| A monoclonal antibody for malaria prevention MR Gaudinski, NM Berkowitz, AH Idris, EE Coates, LSA Holman, ... New England Journal of Medicine 385 (9), 803-814, 2021 | 125 | 2021 |
| Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study MR Gaudinski, EE Coates, L Novik, A Widge, KV Houser, E Burch, ... The Lancet 393 (10174), 889-898, 2019 | 125 | 2019 |
| Activation dynamics and immunoglobulin evolution of pre-existing and newly generated human memory B cell responses to influenza hemagglutinin SF Andrews, MJ Chambers, CA Schramm, J Plyler, JE Raab, M Kanekiyo, ... Immunity 51 (2), 398-410. e5, 2019 | 119 | 2019 |
| Neural differentiation of pluripotent cells in 3D alginate-based cultures A Bozza, EE Coates, T Incitti, KM Ferlin, A Messina, E Menna, Y Bozzi, ... Biomaterials 35 (16), 4636-4645, 2014 | 119 | 2014 |
| Effect of a chikungunya virus–like particle vaccine on safety and tolerability outcomes: a randomized clinical trial GL Chen, EE Coates, SH Plummer, CA Carter, N Berkowitz, ... Jama 323 (14), 1369-1377, 2020 | 101 | 2020 |
| Preferential induction of cross-group influenza A hemagglutinin stem–specific memory B cells after H7N9 immunization in humans SF Andrews, MG Joyce, MJ Chambers, RA Gillespie, M Kanekiyo, ... Science immunology 2 (13), eaan2676, 2017 | 87 | 2017 |
| Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial KV Houser, GL Chen, C Carter, MC Crank, TA Nguyen, MC Burgos Florez, ... Nature medicine 28 (2), 383-391, 2022 | 77 | 2022 |
| Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus DM Herrin, EE Coates, PJ Costner, TJ Kemp, MC Nason, KK Saharia, ... Human vaccines & immunotherapeutics 10 (12), 3446-3454, 2014 | 72 | 2014 |
| Lymph node activation by PET/CT following vaccination with licensed vaccines for human papillomaviruses EE Coates, PJ Costner, MC Nason, DM Herrin, S Conant, P Herscovitch, ... Clinical nuclear medicine 42 (5), 329-334, 2017 | 70 | 2017 |
| Cartilage tissue engineering EE Coates, JP Fisher Molecular, Cellular, and Tissue Engineering, 68-1-68-26, 2018 | 69 | 2018 |
| Low-dose subcutaneous or intravenous monoclonal antibody to prevent malaria RL Wu, AH Idris, NM Berkowitz, M Happe, MR Gaudinski, C Buettner, ... New England Journal of Medicine 387 (5), 397-407, 2022 | 68 | 2022 |
| Photocrosslinked alginate with hyaluronic acid hydrogels as vehicles for mesenchymal stem cell encapsulation and chondrogenesis EE Coates, CN Riggin, JP Fisher Journal of Biomedical Materials Research Part A 101 (7), 1962-1970, 2013 | 64 | 2013 |
| Phenotypic Variations in Chondrocyte Subpopulations and Their Response to In Vitro Culture and External Stimuli EE Coates, JP Fisher Annals of biomedical engineering 38, 3371-3388, 2010 | 62 | 2010 |
| Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial JP Casazza, EM Cale, S Narpala, GV Yamshchikov, EE Coates, ... Nature medicine 28 (5), 1022-1030, 2022 | 42 | 2022 |
| Matrix molecule influence on chondrocyte phenotype and proteoglycan 4 expression by alginate‐embedded zonal chondrocytes and mesenchymal stem cells EE Coates, CN Riggin, JP Fisher Journal of Orthopaedic Research 30 (12), 1886-1897, 2012 | 39 | 2012 |
